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Abstract
The mouse macrophage-like cell line RAW264.7, the most commonly used mouse macrophage cell
line in medical research, was originally reported to be free of replication-competent murine
leukemia virus (MuLV) despite its origin in a tumor induced by Abelson MuLV containing Moloney
MuLV as helper virus. As currently available, however, we find that it produces significant levels of
ecotropic MuLV with the biologic features of the Moloney isolate and also MuLV of the polytropic
or MCF class. Newborn mice developed lymphoma following inoculation with the MuLV mixture
expressed by these cells. These findings should be considered in interpretation of increasingly
widespread use of these cells for propagation of other viruses, studies of biological responses to
virus infection and use in RNA interference and cell signalling studies.
Background
In contrast to most other mouse-derived cell cultures, the
macrophage-like cell line RAW264.7 [1] supports replica-
tion of murine noroviruses and is widely used for this pur-
pose [2]. Further, in studies of a mouse model of severe
respiratory disease, RAW264.7 was found to be uniquely
efficient for propagation of the causative agent, pneumo-
nia virus of mice, and for measuring infection-related
proinflammatory mediators [3]. In addition, because of
ease of cell propagation, high efficiency for DNA transfec-
tion, sensitivity to RNA interference [4], possession of
receptors for many relevant ligands, and other properties,
RAW264.7 has been chosen by the Alliance for Cellular
Signaling as the primary experimental system for their
large-scale study of signaling pathways [5]. The RAW264.7
cell line was derived about 30 years ago from a tumor
developing in a BAB/14 mouse, a BALB/c IgH congenic
strain, inoculated with Abelson murine leukemia virus
(MuLV), a defective transforming virus containing the v-
abl tyrosine kinase oncogene, and replication-competent
Moloney (Mo-MuLV) that served as helper virus [1]. At
the time it was described, tests for presence of replication
competent virus were negative and cells in the American
Type Culture Collection repository (ATCC TIB-71) were
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so designated until recently. As far as we can determine,
ATCC is the major if not sole, commercial source of this
cell line. To date, a Pubmed retrieval lists over 1500 pub-
lications that have used the RAW264.7 cell line in the
research reported.
Results and conclusion
In the course of evaluating RAW264.7 cells for use in iso-
lation and propagation of new isolates of murine norovi-
rus, electron microscopy revealed particles with C-type
morphology (data not shown). To look for expression of
MuLV-encoded protein, RAW264.7 cell pellets were fixed
in formalin and embedded in paraffin; after antigen
retrieval using proteinase K, sections were stained by avi-
din-biotin immunohistochemistry (IHC) using group-
reactive goat anti-Rauscher MuLV p30 antibody (from the
Division of Cancer Cause and Prevention, NCI, Frederick,
MD and obtained from Dr. Sandra Ruscetti). Abundant
expression of MuLV p30 was revealed (Figure 1). Cell sur-
face expression of MuLV gp70 protein (SU) was revealed
by immunofluorescence assay using the broadly reactive
monoclonal antibody 83A25 [6] (data not shown).
In tests for the presence of infectious MuLV, cell-free har-
vests of RAW264.7 supernatants from two separate acqui-
sitions from ATCC were positive using the XC plaque
assay [7] in SC-1 cells [8], indicating the presence of virus
of the ecotropic MuLV class. Titers of several independent
harvests ranged from 101.2 to 104.2 XC plaque-forming
units (pfu) per ml. Lower titers were associated with high
density cell growth and consequent low pH (data not
shown).
Infection of cell cultures of various mouse strains by most
ecotropic MuLVs is regulated by the Fv1 genotype of the
mouse and the tropism of the virus. Thus, Fv1n cells are
permissive for N-tropic and partially restrictive for B-
tropic MuLVs; the reciprocal pattern is observed for cells
of Fv1b mice. A few isolates with long laboratory passage
histories, including Mo-MuLV, are not restricted by either
allele and are termed NB-tropic. XC plaque titration of
RAW264.7 supernatant in NIH3T3 (Fv1n) and BALB3T3
(Fv1b) cells gave essentially identical titers (104.1 and 104.2,
respectively) indicating NB-tropism. Additionally, focal
immunofluoresence assays (IFA) [9] utilizing monoclonal
hybridoma antibody mAb538, specifically reactive with
the Mo-MuLV envelope (SU) protein [10], were positive
in NIH3T3 cells and to about 1000-fold lower titer in Mus
dunni cells, confirming the presence of a virus with eco-
tropic Mo-MuLV biological properties. Why earlier tests
failed to detect ecotropic MuLV in RAW264.7 cells is
unknown but possible explanations include differences in
culture conditions and the health of the cells when
assayed or in sensitivity of the tests used in different labo-
ratories at different times.
It is well established that mouse-passaged ecotropic MuLV
stocks, like the Mo-MuLV helper virus used in establishing
RAW264.7 [1], frequently contain MuLV of other classes –
xenotropic and recombinant MuLVs that result from inter-
action between ecotropic sequences and polytropic, also
referred to as MCF, proviral sequences. Indeed, isolates of
these classes were reported in a stock of Abelson MuLV
complex [11]. Comparative IFA titrations of a RAW264.7
supernatant were performed in NIH3T3 cells using anti-
Mo-MuLV mAb538 and two mAbs that specifically detect
polytropic MuLV SU antigen: 514, reactive with all tested
polytropic MuLVs [11], and HY7, reactive with certain
polytropic subsets [12,13]. Titer estimates of 104 and 104.5
ffu per ml were obtained for polytropic and Moloney eco-
tropic MuLVs, respectively. Negative results with mAbs
reactive with xenotropic MuLVs indicated no significant
population of this class in RAW264.7 supernatants (data
not shown). Thus, RAW264.7 cells express approximately
equal levels of ecotropic Moloney-like and polytropic
MCF MuLVs, with some variation in titer probably
depending on culture conditions.
Inoculation of neonatal mice of sensitive strains with Mo-
MuLV results in development of almost exclusively T cell
lymphoblastic lymphomas (LL), mostly of thymic origin.
To determine the pathogenic potential of harvests from
RAW264.7 cells, we inoculated 1–2 day old Cr:NIH(S)
(NIH Swiss) and BALB/cAnNCr (BALB/c) mice, 0.02 ml
intraperitoneally and in the region of the thymus with a
filtered supernatant of RAW264.7 cells or 264.7 SC-1, a
harvest of SC-1 cells infected with RAW264.7 supernatant
and passaged twice. For comparison, mice were similarly
MuLV p30 expressed by RAW264.7 cells in a formalin-fixed,  paraffin-embedded cell pellet Figure 1
MuLV p30 expressed by RAW264.7 cells in a formalin-fixed, 
paraffin-embedded cell pellet. (Avidin biotin IHC, ×1000).Retrovirology 2008, 5:1 http://www.retrovirology.com/content/5/1/1
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inoculated with Mo-MuLV (molecularly cloned and prop-
agated in SC-1 cells). Controls were uninoculated mice of
the same strains. Mice were obtained from the Division of
Cancer Treatment, NCI, Frederick, MD and studied under
NIAID Animal Care and Use Committee approved proto-
cols and housing. Mice were observed for 8 to 12 months
and necropsied when signs of splenomegaly, lymphaden-
opathy, labored breathing or lethargy were noted or the
experiment was terminated at 12 months. Diagnosis was
based on gross findings, microscopic examination of H&E
stained formalin fixed, paraffin embedded tissues or stud-
ied by IHC using the anti-p30 antibody, anti-CD3 for T-
cell lineage identification (DAKO Corporation, Carpinte-
ria, CA Catalog # A452), and anti-PAX5 for B-cell lineage
(Goat anti-Pax 5, Santa Cruz Biotechnology, Santa Cruz,
CA, Catalog #sc-1974) [14]. Criteria for histopathological
diagnosis were as described [15].
As shown in Table 1, there were no significant differences
in tumor incidence between NIH Swiss and BALB/c recip-
ients but virus dose was clearly an important variable for
those inoculated with the viruses produced by RAW264.7
cells (264.7MuLVmix), with higher concentrations tend-
ing to give shorter latencies and more diversity in pathol-
ogy. Mo-MuLV induced mostly T-cell LL, characterized
histologically by diffuse growth of CD3+ T-cell lymphob-
lasts usually originating in the thymus and metastasizing
to the spleen, liver and other organs. Most mice presented
with significantly enlarged thymus (16/19), spleen
weights of over 600 mg (18/19) and variable lymphaden-
opathy. Mice injected with 264.7-MuLVmix expressed
MuLV p30 in spleen (Figure 2), megakaryocytes, and
many tissues prior to tumor development and in all lym-
phomas examined (e.g., Figure 3). Splenomegaly and
lymphadenopathy were variable with spleen weights
ranging from 100 to 1800 mg. The majority of hemat-
opoietic neoplasms were classified as LL (26/34). Of
these, 19 were of T-cell origin, CD3+ and PAX5-; 13 were
associated with enlarged thymus (Figure 4). In contrast to
CD3+ Mo-MuLV-induced LL (Figure 5), the remaining
seven LL were of B-cell origin, based on PAX5+ IHC (Fig-
ure 6) and CD3 negativity. Spleen weights ranged from
450 to 770 mg and lymph node size was variable. In addi-
tion, one BALB/c mouse had an early splenic marginal
MuLV p30 expression in spleen 8 weeks post injection of  264.7-MuLV, SC-1 prior to lymphoma development (IHC,  hematoxylin, ×100) Figure 2
MuLV p30 expression in spleen 8 weeks post injection of 
264.7-MuLV, SC-1 prior to lymphoma development (IHC, 
hematoxylin, ×100).
Table 1: Comparative Pathogenicity of 264.7MuLVs and Mo-MuLV in Mice
Diagnosis3
Mouse 
Strain
Inoculum Virus dose1 #pos/#inoc2 Latency 
(days)
% positive LL-T LL-B Erythroid Other
NIH Swiss Mo-MuLV 104.4 6/6 87 +/- 16 100 4 0 24 0
102.2 10/10 93 +/- 13 100 10 0 0 0
RAW264.7 cell-free supernatant 101.0 5/7 259 +/- 68 71 3 0 1 15
102.5 12/15 163 +/- 68 80 5 4 3 0
264.7-MuLV, SC-1 passage 102.2 3/3 146 +/- 24 100 2 1 0 0
None - 0/5
BALB/c Mo-MuLV 104.4 5/5 98 +/- 14 100 5 0 0 0
RAW264.7 cell-free supernatant 101.0 2/2 255 100 1 0 1 0
102.5 7/12 168 +/- 53 58 4 24 10
264.7-MuLV SC-1 passage 102.2 5/5 216 +/- 84 100 4 0 0 16
None - 0/4
1 pfu/mouse of ecotropic MuLV, based on XC plaque titration in SC-1 cells; polytropic MuLV titer not determined.
2 number of mice positive for hematopoietic disease/number inoculated.
3 LL, lymphoblastic lymphoma;, T, T-cell lineage; B, B-cell lineage; erythroid, erythroleukemia (PAX5 and CD3 negative).
4 One case also had early Thymic T-LL.
5 Mast cell tumor, spleen and bone marrow (366d post-inoculation).
6 Early splenic marginal zone lymphoma (295d post-inoculation) ; also very early T-LL in thymus.Retrovirology 2008, 5:1 http://www.retrovirology.com/content/5/1/1
Page 4 of 6
(page number not for citation purposes)
zone B cell lymphoma (MZL) as well as early thymic T-LL.
To our knowledge, spontaneous splenic MZL has not been
reported in this strain. There are sporadic reports of exog-
enous virus induction of B cell lymphomas in mice by a
variety of ecotropic and polytropic MuLVs [16,17], none
to our knowledge involving Mo-MuLV except for pre-B LL
induction in Eμ-myc transgenic mice [18]. Pre-B, imma-
ture B cells and plasma cells are the target cells of Abelson
MuLV [19] and mice infected with the LP-BM5 complex,
which includes a defective immunodeficiency-inducing
virus, develop transplantable clonal B-cell populations
[20]. We did not detect Abelson transforming capacity in
tissue culture assays (data not shown), but it is conceiva-
ble that B-cell LLs found in our study might be causally
related to the Abelson genome present in RAW264.7 cells.
Alternatively, B cell pathology may be associated with the
polytropic virus population present in RAW264.7 super-
natants, likely in synergy with Mo-MuLV. Further testing
with cloned virus preparations would be necessary to
resolve these possibilities.
Six of 34 264.7MuLVmix- and 2 of 16 MoMuLV-induced
tumors were non-lymphoid and diagnosed as erythro-
leukemia based on splenomegaly with a high frequency of
erythroid cells and lack of reactivity with CD3 and PAX5.
These neoplasms, not usually seen following Mo-MuLV
MuLV p30 in splenic follicular B-cells and megakaryocytes in a  mouse injected with 264.7-MuLV and that developed thymic  lymphoma at 119 days (IHC, hematoxylin, ×200) Figure 3
MuLV p30 in splenic follicular B-cells and megakaryocytes in a 
mouse injected with 264.7-MuLV and that developed thymic 
lymphoma at 119 days (IHC, hematoxylin, ×200).
Thymic lymphoma induced by 264.7-MuLV, 164 days post  injection Figure 4
Thymic lymphoma induced by 264.7-MuLV, 164 days post 
injection. Note large spleen.
Thymic lymphoma in 264.7-MuLV infected mouse showing  CD3+ lymphoma cells in lung metastases (IHC, hematoxylin,  ×200) Figure 5
Thymic lymphoma in 264.7-MuLV infected mouse showing 
CD3+ lymphoma cells in lung metastases (IHC, hematoxylin, 
×200).
PAX5 expression in bone marrow metastases of a B-cell lym- phoma induced by RAW 264.7-MuLV (IHC, hematoxylin,  ×100) Figure 6
PAX5 expression in bone marrow metastases of a B-cell lym-
phoma induced by RAW 264.7-MuLV (IHC, hematoxylin, 
×100).Retrovirology 2008, 5:1 http://www.retrovirology.com/content/5/1/1
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infection, may be related to the generalized hyperplasia of
hematopoietic lineages, including erythroid, reported in
pre-leukemic Mo-MuLV-infected mice [21].
A further unusual finding was a mast cell tumor, a rarely
seen mouse neoplasm that cannot unequivocally be con-
sidered related to the virus inoculation.
As shown in this report, RAW264.7 cells as currently avail-
able from ATCC express ecotropic and polytropic MuLVs.
The ecotropic virus has biological properties of the Mo-
MuLV helper virus of the Abelson virus complex that
induced the tumor from which the cell line derived. Cell-
free culture supernatants containing the mixed virus pop-
ulation induced hematopoietic disease in newborn mice,
primarily LL that were mostly of T cell type, as is charac-
teristic of Mo-MuLV lymphomagenesis, but also some of
B cell origin. This tumor-inducing potential may con-
found pathogenicity testing of unrelated viruses propa-
gated in RAW264.7, especially in newborn mice. Adult
mice are susceptible to infection by Mo- and other MuLVs,
however [22,23], and mixed infection of MuLVs with
related and unrelated viruses may have effects not directly
attributable to lymphomagenicity. For example, radia-
tion-induced RadLV enhances expression of MHC Class I
genes [24] as does Mo-MuLV in cell culture [25]. Syner-
gism between different retroviruses of low pathogenicity
induces a rapidly fatal neurological disease [26], ecotropic
MuLV potentiates LDV-related paralytic disease [27] and
Mo-MuLV potentiates polyomavirus-induced runting syn-
drome [28].
Ecotropic MuLV infection of adult mice has been shown
to increase B-cell proliferation, serum immunoglobulin M
levels and expression of transcripts associated with B cell
activation [23]. Further, infection of bone marrow cells
with MoMuLV or bone marrow and primary B cells by
Abelson MuLV induces expression of activation-induced
cytidine deaminase (AID) by activating NFκB [29,30].
Ectopic expression of AID can result in generalized
somatic hypermutation [31].
Such illustrations of unanticipated consequences of MuLV
infection as well as conceivable disruptive effects of MuLV
replication, including integration into cellular DNA and
cell surface expression of MuLV antigens, suggest caution
in experimental design and data interpretation in studies
utilizing RAW264.7 cells.
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